^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SHR-A1904
i
Other names: SHR-A1904
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
EMD Serono, Jiangsu Hengrui Pharma
Drug class:
CLDN18.2-targeted antibody-drug conjugate
Related drugs:
20d
SHR-A1904-301: SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor (clinicaltrials.gov)
P1, N=924, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
capecitabine • oxaliplatin • SHR-A1904 • adebrelimab (SHR-1316)
1m
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor (clinicaltrials.gov)
P1, N=924, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
New P1 trial • Metastases
|
capecitabine • oxaliplatin • SHR-A1904 • SHR-A1912
over1year
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS (clinicaltrials.gov)
P1/2, N=83, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Initiation date: Dec 2022 --> May 2022
Trial initiation date • Metastases
|
CLDN18 (Claudin 18)
|
SHR-A1904
Share via
